FUCON Capsule

For the treatment of spasmodic pain, esophageal

spasm cholecystitis, choledocholithiasis, uriasis cystospasm, dysuria, pollakisuria, and spasmodic dysmenorrhea.

Dosage: 1 - 2 capsules three to four times daily.

Hyoscine is contraindicated in patients with closed-angle glaucoma, or in patients with a narrow-angel between the iris and the cornea and with prostatic enlargement, patients in whom it may lead to urinary retention, and in those with paralytic

ileus or pyloric stenosis and patients with history of hypersensitivity.

Side effects include dryness of the mouth with difficulty in swallowing and talking, thirst, dilation of the pupils (mydriasis), loss of accommodation (cycloplegia) and photophobia, flushing and dryness of the skin, transient bradycardia followed by tachycardia and urinary urgency, difficulty and retention, vomiting, giddiness, retrosternal pain, CNS depression, coma, circulatory and respiratory failure.

1. Concurrent administration of fucon with tricyclic antidepressant, monoamine oxidase inhibitors, antihistamines, amantadine and disopyramide can potentiate the antimuscarinic side effect of fucon.

2. Fucon enhances tachycadic effects of B-adrenergic agents.

3. Fucon may cause reduced absorption of ketoconazole.

4. The gastro-intestinal effects of dopamine antagonist such as metoclopramide and domperidone can be antagonised by fucon.

Hyoscine should be used with caution in children and in geriatric patients with myasthenia gravis and with fever. Hyoscine may cause drowsiness, patients so affected should not drive or operate machinery. Patients should abstain from alcohol. Use with caution in patients with impaired metabolic, liver or kidney functions, as adverse CNS effects are more likely to occur in these patients. Because of a possible mydriatic effect, Hyoscine should not be administered to patients with glaucoma.

1. Hyoscine-N-butylbromide is an antimuscarinic agent with central and peripheral actions. It is a more powerful suppressant of salivation than atropine.

2. Hyoscine-N-Butylbromide is being poorly absorbed from the gastro-intestinal tract and does not readily pass the blood brain barrier.